These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30730287)

  • 41. A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.
    Andreu F; Colom H; Elens L; van Gelder T; van Schaik RHN; Hesselink DA; Bestard O; Torras J; Cruzado JM; Grinyó JM; Lloberas N
    Clin Pharmacokinet; 2017 Aug; 56(8):963-975. PubMed ID: 28050888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population Pharmacokinetic Analysis for Model-Based Therapeutic Drug Monitoring of Tacrolimus in Chinese Han Heart Transplant Patients.
    Cheng Y; Chen J; Lin X; Qiu H; Zhang J
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):89-100. PubMed ID: 36482138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients.
    Zhang J; Zhang X; Liu L; Tong W
    Transplant Proc; 2010 Nov; 42(9):3459-64. PubMed ID: 21094797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
    Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
    Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.
    Uno T; Wada K; Matsuda S; Terada Y; Oita A; Kawase A; Takada M
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):665-673. PubMed ID: 29691732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.
    Zhao W; Fakhoury M; Baudouin V; Storme T; Maisin A; Deschênes G; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2013 Feb; 69(2):189-95. PubMed ID: 22706623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations.
    Vadcharavivad S; Praisuwan S; Techawathanawanna N; Treyaprasert W; Avihingsanon Y
    J Clin Pharm Ther; 2016 Jun; 41(3):310-28. PubMed ID: 27191538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
    Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
    Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
    García-Roca P; Medeiros M; Reyes H; Rodríguez-Espino BA; Alberú J; Ortiz L; Vásquez-Perdomo M; Elizondo G; Morales-Buenrostro LE; Mancilla Urrea E; Castañeda-Hernández G
    Arch Med Res; 2012 May; 43(4):283-7. PubMed ID: 22704849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Population pharmacokinetics of tacrolimus in Chinese renal transplant patients].
    Zhang GM; Li L; Chen WQ; Bi SS; Liu X; Zhang XL; Lu W
    Yao Xue Xue Bao; 2008 Jul; 43(7):695-701. PubMed ID: 18819472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
    Chen X; Wang DD; Xu H; Li ZP
    Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers.
    Xue L; Zhang H; Ma S; Rui JZ; Miao LY
    Pharmacology; 2011; 88(5-6):288-94. PubMed ID: 22075549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
    Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
    Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Importance of hematocrit for a tacrolimus target concentration strategy.
    Størset E; Holford N; Midtvedt K; Bremer S; Bergan S; Åsberg A
    Eur J Clin Pharmacol; 2014 Jan; 70(1):65-77. PubMed ID: 24071959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
    Spierings N; Holt DW; MacPhee IA
    Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: A systematic review.
    Khamlek K; Komenkul V; Sriboonruang T; Wattanavijitkul T
    Br J Clin Pharmacol; 2024 Feb; 90(2):406-426. PubMed ID: 37714740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
    Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
    Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.
    Størset E; Holford N; Hennig S; Bergmann TK; Bergan S; Bremer S; Åsberg A; Midtvedt K; Staatz CE
    Br J Clin Pharmacol; 2014 Sep; 78(3):509-23. PubMed ID: 25279405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.